Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (560)	3/31/1998 5:02:00 PM
From: Jim Roof	Respond to of 4634

There are no reasons why approval will not be given. Everything in Hextend is already well understood from a medical perspective. Without approval I would expect 1 or less myself. It's the market for the approved product that we (and many others) disagree on. If the price for Hextend is within 10-20% of the price of hetastarch then I think it just a matter of time before Hextend becomes the standard for treatment. I think the overall marketing plan is to show that even with a slightly higher cost for the fluids, the lower costs for other ancillary treatments more than makes up for the small increase. More studies will need to be done IMHO to lock this in. I think Phase III data shows some inclinations but the study was only designed to show equivalency and safety. Jim